| |  Online-Ressource |
|---|
| Verfasst von: | Goldschmidt, Hartmut [VerfasserIn]  |
|---|
| | Bärtsch, Marc-Andrea [VerfasserIn] |
|---|
| | Schlenzka, Jana [VerfasserIn] |
|---|
| | Becker, Natalia [VerfasserIn] |
|---|
| | Habermehl, Christina [VerfasserIn] |
|---|
| | Hielscher, Thomas [VerfasserIn] |
|---|
| | Raab, Marc-Steffen [VerfasserIn] |
|---|
| | Hillengaß, Jens [VerfasserIn] |
|---|
| | Sauer, Sandra [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Luntz, Steffen P. [VerfasserIn] |
|---|
| | Jauch, Anna [VerfasserIn] |
|---|
| | Hose, Dirk [VerfasserIn] |
|---|
| | Seckinger, Anja [VerfasserIn] |
|---|
| | Brossart, Peter [VerfasserIn] |
|---|
| | Goerner, Martin [VerfasserIn] |
|---|
| | Klein, Stefan [VerfasserIn] |
|---|
| | Schmidt-Hieber, Martin [VerfasserIn] |
|---|
| | Reimer, Peter [VerfasserIn] |
|---|
| | Graeven, Ullrich [VerfasserIn] |
|---|
| | Fenk, Roland [VerfasserIn] |
|---|
| | Haenel, Mathias [VerfasserIn] |
|---|
| | Martin, Hans [VerfasserIn] |
|---|
| | Lindemann, Hans W. [VerfasserIn] |
|---|
| | Scheid, Christoph [VerfasserIn] |
|---|
| | Nogai, Axel [VerfasserIn] |
|---|
| | Salwender, Hans [VerfasserIn] |
|---|
| | Noppeney, Richard [VerfasserIn] |
|---|
| | Besemer, Britta [VerfasserIn] |
|---|
| | Weisel, Katja [VerfasserIn] |
|---|
| Titel: | Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma |
|---|
| Titelzusatz: | the randomized GMMG phase III trial ReLApsE |
|---|
| Verf.angabe: | Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 21 July 2020 |
|---|
| Umfang: | 11 S. |
|---|
| Fussnoten: | Gesehen am 28.07.2020 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 35(2021), 4, Seite 1134-1144 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted. |
|---|
| DOI: | doi:10.1038/s41375-020-0948-0 |
|---|
| URL: | Volltext: https://doi.org/10.1038/s41375-020-0948-0 |
|---|
| | Volltext: https://www.nature.com/articles/s41375-020-0948-0 |
|---|
| | DOI: https://doi.org/10.1038/s41375-020-0948-0 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1725647060 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma / Goldschmidt, Hartmut [VerfasserIn]; 21 July 2020 (Online-Ressource)
